

Advanced Human Imaging inks a deal with Jana Care Inc to integrate its digitally connected fingerstick blood tests into CompleteScan.

Highlights

- **Jana is used in over 1,500 clinics by over 10,000 health workers with more than 200,000 patients.¹**
- **Jana partners with some of the world most respected healthcare organizations including Siemens Healthineer, NUH and Astra Zeneca.**
- **Jana and AHI will work to bring affordable digitally connected care to everyone.**
- **AHI will have an option to acquire a strategic interest in Jana.**
- **The *Aina* device brings a wet lab onto a user's mobile phone.**

Advanced Human Imaging, Ltd. (ASX: AHI) is pleased to announce that it has signed a binding terms sheet with US based on device blood pathology company **Jana Care Inc. (Jana)**.

Jana has developed and patented an on-device blood screening tool called *Aina*, the patented *Aina* device is capable of providing rapid, accurate readouts of key blood chemistry elements in several chronic disease categories: cardiovascular, renal and metabolic (CVRM).

The *Aina* tests include diabetes - HbA1c, and glucose; heart disease - total cholesterol, triglycerides, total HDL cholesterol, NT-pro-BNP and Potassium; and serum Creatinine and hemoglobin for kidney disease. HbA1c has received US FDA 510k clearance.

The *Aina* device delivers rapid, accurate readouts that are extremely valuable for its healthcare partner's and patients that have deployed personal health management apps like *CompleteScan* via their carers, life/health insurers, wellness managers, fitness organizations, and telehealth doctors/facilities. The *Aina* device avoids the necessity for the patient/user to go to a medical facility or phlebologist to provide blood and then wait for the results over days. The *Aina* device diagnostic solution will be provided by AHI via *CompleteScan* to its partners for their onward use by selected persons whose blood chemistry information is needed on a timely and accurate basis.

AHI would include Jana's *Aina* device as an add-on to its suite of healthcare information technologies that run on a user's smartphone. The *Aina* device - the size of a matchbox - uses a very small strip of paper treated with analytes that react to a drop of blood from the user. The strip is inserted into the *Aina* device whose proprietary reading technology provides results very quickly and transfers that data to the user's smartphone into which it has been plugged through a port or connected via Bluetooth.

Aina brings lab quality blood tests to individuals, doctors, healthcare workers and their patients with low cost easy-to-use capabilities. The technology behind the *Aina* device is transferring a wet chemistry lab into dry chemistry test strips, with accessibility and affordability in mind.

From a wet lab to a dry strip, Jana engineers layers of porous materials, like paper, coated with dry chemistry to make diagnostic tests. Upon contact with blood, capillary action drives passive flow across or through a

¹ As disclosed on Jana Care website www.janacare.com

strip, the flowing liquid activates the chemistry, and the chemistry creates an optical signal that *Aina* can read.

Aina harnesses the full arsenal of biochemistry immunoassays, enzymatic assays, and chemical affinity to create the right test for the desired biomarker. The *Aina* universal reader, utilizes signals on the test strip that are read by the device which contains an optical reader capable of reading multiple modalities (colorimetric and fluorescent).

The proprietary design of the optics is compact, affordable, and allows multiple assays to be analysed on the same reader. The flexibility of *Aina* allows it to be used for tests with further menu expansion underway, all connected via a mobile platform.

Importantly, among the many advantages of having a mobile connected platform. Jana is able to reprogram *Aina* devices in the field for new tests seamlessly with over-the-air software upgrades and also identify devices that need to be serviced and troubleshoot them remotely to ensure quality and reliability at scale.

How is Jana’s technology different than its competitors?

Jana’s technology is designed for screening, primary care, and home monitoring settings. There is an unmet need for an affordable diagnostic system for chronic disease management in primary and community care settings. Diagnostic tests using array technologies and microfluidics require expensive equipment and capital-intensive manufacturing. Though these types of diagnostics might be suitable for established hospitals which require testing hundreds of samples at a time, they are not designed to fit the needs of community and home care.

Jana has been successful in partnering with major healthcare distributors, hospitals, and medical research organizations, such as, Siemens Healthineer, National University Hospital of Singapore (NUH) and Astra Zeneca. Jana is very proud to have *Aina* being utilized in over 1,500 clinics, with over 10,000 healthcare workers across more than 200,000 patients². The patients are a fraction of the available market when considering 50% of Type 2 Diabetes globally remains undiagnosed and barely 10% of patients meet therapy goals. The *Aina* novel point-of-care screening platform enables early detection and management of personal care with conditions such as Type 2 Diabetes being just one of Jana’s care diagnostics.

Jana’s *Aina* device and platform will be combined into the AHI, *CompleteScan* platform. The AHI team will work with the Jana team to advance the integration solution and messaging for the use of the combined applications for partners and consumers all over the world.

Under the terms of the Agreement, the companies will combine the Jana “*Habits*” App into the CompleteScan platform with the first demonstratable product being made available in Q3 2021.

The terms of the Binding Terms Sheet are disclosed as follows.

Summary of Material Terms:

Item	Summary/Details
Parties	Advanced Human Imaging Limited (AHI) Jana Care Inc (Jana)
Agreement	Binding Terms Sheet

² As disclosed on Jana Care Website www.janacare.com

Conditions Precedent	<p>The investment contemplated within the Binding Terms Sheet is conditional upon AHI completing due diligence on Jana within 90 days from the date of execution of the Binding Terms Sheet to AHI's satisfaction (Condition).</p> <p>If the due diligence is not satisfied, then AHI may choose to not proceed with the \$8,000,000 investment in cash and AHI shares.</p>
Formal Agreements to be concluded	<p>While the Binding Terms Sheet is legally binding, AHI and Jana intend to enter formal agreements to further set out the terms of the integration of the platforms into <i>MultiScan</i> capabilities and related intellectual property to integrate them into the partner platform/technology.</p> <p>The parties intend to enter into the following formal agreements:</p> <ul style="list-style-type: none"> • Commercial Agreement; • The Software Development Kit, End User License Agreement; • Support Agreement; • Data Processing Agreement and • Investment Agreement. <p>Under the terms of the Binding Terms Sheet, all of the aforementioned agreements will be concluded no later than 60 days from the signing of the Binding Terms Sheet.</p>
Option to invest	<p>Subject to satisfaction of the Condition, AHI will have the right to invest a total of up to USD\$8,000,000 into Jana, comprising:</p> <ul style="list-style-type: none"> • an option to invest USD\$5,000,000 in cash; and • subject to shareholder approval, an option to invest up to USD\$3,000,000 in AHI ordinary shares (Investment Shares). • AHI shares will be subject to a voluntary lock up for up to 180 days from the date of issue. <p>The option to undertake the investment will be open to AHI for 120 days from signing of the binding terms sheet.</p> <p>If AHI exercises the option to invest in Jana through the issue of the Investment Shares, and shareholders do not approve the issue of the Investment Shares within 60 days of such exercise, AHI may instead pay Jana US\$3,000,000 in cash.</p>
Convertible Note Investment	<p>AHI will invest in the current convertible note round being offered by Jana. The amount AHI will participate will be a total of USD\$500,000 investment.</p>
Revenue based equity	<p>AHI has a further right for a period of 3 years from the date of the first integrated product launch, to acquire a further 10% of Jana stock.</p> <p>AHI will be issued 1% of Jana for every USD\$1,000,000 in gross revenue to Jana under the revenue sharing arrangement.</p> <p>In the event AHI decides not to take up the investment in Jana, AHI will still retain the right to equity via revenue generation, with the only change being 1% of Jana shares for every USD\$2m in gross revenue to Jana.</p>
Revenue Sharing	<p>AHI and Jana will share the revenue from the sale and distribution of the <i>Aina</i> device, less the amount equal to the costs that Jana incurs for the standard cost</p>

	of manufacture of Jana processing devices (Manufacturing Costs Amount), on a 50/50 basis.
Financial Impact	AHI does not expect any immediate material financial return as a result of entering into this agreement. AHI expects to start generating licence and other fees from the commercial arrangement in the future (which cannot be forecast at this time).
Governing Law	New York

Vlado Bosanac, Chief Executive Officer of AHI, said:

“The commercial distribution arrangement we have undertaken with Jana is an extremely important addition to the remote care and health assessment platform we are delivering to our partners and the vast communities they service around the world. The work Jana has and is doing in the care and identification of chronic disease is of paramount importance and a perfect addition to our offering.

The use case is powerful, when a user performs a FaceScan or a BodyScan we are able to detect a number of potential risk parameters that relate to chronic diseases. These markers are not dissimilar to the checks a doctor would perform when a patient is attending the doctors practice. If the performed scans identify any of the markers, this will assist the care provider in the need to facilitate a blood test, at which time via the *Aina* device we will facilitate the draw, analysis and diagnostic reports for both the patient, doctor and care provider.

I am excited with this latest partnership and how it brings AHI a full circle approach to individualized care and identification. My intention is to support all on-device capabilities by the close of 2021, with FaceScan, BodyScan, DermaScan, MSKScan and VeniScan”.

Rajen Dalal, Chair and Chief Executive Officer of Jana Care said:

“Jana Care’s quantitative digital fingerstick tests for heart, kidney, and diabetes, combined with AHI’s MultiScan suite of optical imaging applications using the smartphone, completes the circle to provide a 360-degree view of an individual’s health and wellness.

COVID put to rest any lingering doubts there may have been regarding the potential value of remote monitoring with smartphone-based telemedicine and teleradiology. We are only at the beginning of this digital health revolution and will see the impact of these technologies grow in the near future as they help reduce the progression of chronic disease and reduce healthcare costs”.

About Jana Care Technologies Inc.

Jana Care is a global company developing biomarker assays for its proprietary digital health platform with the goal of improving health outcomes for people living with heart, kidney and metabolic conditions. Jana’s unique approach combines low-cost diagnostics, lifestyle coaching, and predictive analytics, all delivered through a smartphone. Jana’s products provide actionable information to both patients and health care providers. Jana’s international team works between its offices in Boston, MA and Bangalore, India

For more information please visit: www.janacare.com

ASX Announcement
Thursday 20th May 2021



For more information contact:

Vlado Bosanac,
Chief Executive Officer
Advanced Human Imaging Limited
E: admin@advancedhumanimaging.com

Steven Richards,
Chief Financial Officer
Advanced Human Imaging Limited
E: admin@advancedhumanimaging.com

About Advanced Human Imaging:

The Company has developed and patented a proprietary technology that enables its users to privately check, track, and accurately assess their dimensions, solely using a smartphone. AHI refers to this physical measurement and analysis tool as “BodyScan.” AHI is globalizing its technology to assist governments, sporting organizations, individuals, communities, and populations live healthier lives.

AHI’s patented technology allows individuals, via an automated system, to take a series of images of themselves using a smartphone which delivers accurate and repeatable measurements across the individual’s entire body. These measurements allow the individual to understand his/her dimensions and the physical changes which they are undergoing through the provision of care, diet, exercise, and lifestyle. Further, the images that AHI captures also provide the individual with an understanding of their health risk related to certain chronic diseases (including obesity and related diseases such as diabetes). AHI uses global standards set by the World Health Organization (WHO), and the International Diabetes Federation (IDF) when assessing and deriving this information feedback loop.

The Company has recently advanced its technology to run these complex mathematical algorithms directly on the user’s smartphone, rather than limiting that computation to the Cloud. AHI’s overarching technology strategy has been to take advantage of the mobile device’s accelerated performance, specifically by utilizing on-device general-purpose Graphics Processing Units (GPU) for the safe and private processing and computation of the individual's personal health data.

AHI delivers a non-invasive, highly accurate and privacy-sensitive solution that returns results within seconds. The Company leverages machine-learning and computer vision to analyze images, detect pose and joint features, and create non-personally identified data for measurement estimation. AHI takes advantage of dedicated GPU libraries such as TensorFlow Lite (Android) and Metal (Apple) to run prediction models, which have been trained with a substantial and diverse human data set proprietary to the company from around the globe, which is enabled on the device to process multiple captured images in fractions of a second. The result is a solution that runs on-device and does not sacrifice speed, security, or privacy. Images and private information never leave the users personal device, ensuring security and privacy standards are met across global regions and requirements. This unrivalled process allows us to produce exceptional results and simplify the output of useful, reliable, digital measurements and remove the human error otherwise present in traditional methods such as tape measurements.

Advanced Human Imaging’s expansion over 2020 saw the delivery of a MultiScan platform, which delivers a further diverse of biometric measurements through expanded on device captures across the body, Face, and skin, delivering vital signs and skin conditions, accelerating traditional information gathering and analysis methods with rapid and accurate individualized health data.

For more information please visit: www.advancedhumanimaging.com

*This announcement has been approved by the board of Advanced Human Imaging Limited.